Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.
Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL. Vesikari T, et al. Among authors: beeslaar j. J Pediatric Infect Dis Soc. 2016 Jun;5(2):180-7. doi: 10.1093/jpids/piv064. Epub 2016 Jan 23. J Pediatric Infect Dis Soc. 2016. PMID: 26803328 Free PMC article. Clinical Trial.
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators. Richmond PC, et al. Among authors: beeslaar j. Lancet Infect Dis. 2012 Aug;12(8):597-607. doi: 10.1016/S1473-3099(12)70087-7. Epub 2012 May 7. Lancet Infect Dis. 2012. PMID: 22569484 Clinical Trial.
Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL. Vesikari T, et al. Among authors: beeslaar j. J Pediatric Infect Dis Soc. 2016 Jun;5(2):152-60. doi: 10.1093/jpids/piv039. Epub 2015 Aug 4. J Pediatric Infect Dis Soc. 2016. PMID: 26407272 Free PMC article. Clinical Trial.
A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.
Ostergaard L, Lucksinger GH, Absalon J, Beeslaar J, Eiden J, Jansen KU, York LJ, Quinn A, Graversen ME, Perez JL. Ostergaard L, et al. Among authors: beeslaar j. Vaccine. 2016 Mar 14;34(12):1465-71. doi: 10.1016/j.vaccine.2016.01.044. Epub 2016 Feb 1. Vaccine. 2016. PMID: 26845739 Free article. Clinical Trial.
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Lee SS, Perez JL; 6108A12001 Study Investigators. Marshall HS, et al. Among authors: beeslaar j. Lancet Infect Dis. 2017 Jan;17(1):58-67. doi: 10.1016/S1473-3099(16)30314-0. Epub 2016 Oct 11. Lancet Infect Dis. 2017. PMID: 27745812 Clinical Trial.
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Prégaldien JL, Ginis J, Staerke NB, Perez JL; B1971009 and B1971016 Trial Investigators. Ostergaard L, et al. Among authors: beeslaar j. N Engl J Med. 2017 Dec 14;377(24):2349-2362. doi: 10.1056/NEJMoa1614474. N Engl J Med. 2017. PMID: 29236639 Free article. Clinical Trial.
Modeling excess zeroes in an integrated analysis of vaccine safety.
Maansson R, Radley D, Jiang Q, Beeslaar J, Patterson S, Absalon J, Perez J. Maansson R, et al. Among authors: beeslaar j. Hum Vaccin Immunother. 2018 Jun 3;14(6):1530-1533. doi: 10.1080/21645515.2018.1433972. Epub 2018 Feb 23. Hum Vaccin Immunother. 2018. PMID: 29393713 Free PMC article.
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
Perez JL, Absalon J, Beeslaar J, Balmer P, Jansen KU, Jones TR, Harris S, York LJ, Jiang Q, Radley D, Anderson AS, Crowther G, Eiden JJ. Perez JL, et al. Among authors: beeslaar j. Expert Rev Vaccines. 2018 Jun;17(6):461-477. doi: 10.1080/14760584.2018.1483726. Epub 2018 Jun 22. Expert Rev Vaccines. 2018. PMID: 29883226 Free article. Review.
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T, Østergaard L, Beeslaar J, Absalon J, Eiden JJ, Jansen KU, Jones TR, Harris SL, Maansson R, Munson S, O'Neill RE, York LJ, Perez JL. Vesikari T, et al. Among authors: beeslaar j. Vaccine. 2019 Mar 14;37(12):1710-1719. doi: 10.1016/j.vaccine.2018.11.073. Epub 2019 Feb 12. Vaccine. 2019. PMID: 30770221 Clinical Trial.
21 results